Fuel and brake of memory T cell inflation.
CD8 T cell
Cytomegalovirus infection
Memory inflation
Journal
Medical microbiology and immunology
ISSN: 1432-1831
Titre abrégé: Med Microbiol Immunol
Pays: Germany
ID NLM: 0314524
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
received:
30
01
2019
accepted:
21
02
2019
pubmed:
11
3
2019
medline:
18
12
2019
entrez:
11
3
2019
Statut:
ppublish
Résumé
Memory T cell inflation is a process in which a large number of effector memory T cells accumulates in peripheral tissues. This phenomenon is observed upon certain low level persistent virus infections, but it is most commonly described upon infection with the β-herpesvirus Cytomegalovirus. Due to the induction of this large pool of functional effector CD8 T cells in peripheral tissues, the interest in using CMV-based vaccine vectors for vaccination purposes is rising. However, the exact mechanisms of memory T cell inflation are not yet fully understood. It is clear that repetitive exposure to antigen is a key determinant for memory inflation, and therefore the viral inoculum dose and the subsequent number of viral reactivation events strongly impact on the magnitude of the inflationary T cell pool. In addition, the number of CMV-specific CD8 T cells that is able to sense these reactivation events affects the size of the inflationary T cell pool. In the following, we will discuss factors that either promote or limit T cell inflation from both the virus and host perspective. These factors mostly operate by influencing the amount of available antigen or by affecting the T cell pool that is able to respond to the antigen. Furthermore, we will discuss the recent use of CMV-based vaccines in pre-clinical experimental settings, where these vectors have shown promising results by inducing prolonged effector memory T cell responses to foreign-introduced epitopes and thereby provided protection from subsequent virus or tumour challenges.
Identifiants
pubmed: 30852648
doi: 10.1007/s00430-019-00587-9
pii: 10.1007/s00430-019-00587-9
doi:
Substances chimiques
Antigens, Viral
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
329-338Subventions
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
ID : 310030_146140
Organisme : ETH Zürich
ID : FEL29 15-2
Références
Cell Rep. 2015 Nov 10;13(6):1125-1136
pubmed: 26526997
J Immunol. 2007 Aug 15;179(4):2195-202
pubmed: 17675479
Science. 2016 Feb 12;351(6274):714-20
pubmed: 26797147
J Virol. 2000 Dec;74(24):11495-503
pubmed: 11090146
Viral Immunol. 2017 Jul/Aug;30(6):438-450
pubmed: 28418771
Cell Rep. 2015 Nov 10;13(6):1137-1148
pubmed: 26526996
Viral Immunol. 2011 Aug;24(4):351-5
pubmed: 21721929
J Immunol. 2017 Sep 1;199(5):1737-1747
pubmed: 28768725
Eur J Immunol. 2010 Oct;40(10):2762-8
pubmed: 20722077
PLoS Pathog. 2011 Oct;7(10):e1002295
pubmed: 21998590
PLoS Pathog. 2011 Aug;7(8):e1002214
pubmed: 21901102
Nat Immunol. 2011 Jul 31;12(9):908-13
pubmed: 21804558
J Exp Med. 1994 Jan 1;179(1):185-93
pubmed: 8270864
Immun Ageing. 2012 Oct 31;9(1):23
pubmed: 23114110
PLoS Negl Trop Dis. 2011 Aug;5(8):e1275
pubmed: 21858240
J Immunol. 2006 Jul 1;177(1):450-8
pubmed: 16785542
Eur J Immunol. 2014 Apr;44(4):1046-57
pubmed: 24356925
Front Immunol. 2018 Jan 10;8:1953
pubmed: 29367854
Immunity. 2008 Oct 17;29(4):650-9
pubmed: 18957267
Eur J Immunol. 2012 Feb;42(2):320-9
pubmed: 22102057
Nat Med. 2009 Mar;15(3):293-9
pubmed: 19219024
Vaccine. 2009 Mar 26;27(15):2177-87
pubmed: 19201385
Nature. 2011 May 26;473(7348):523-7
pubmed: 21562493
J Virol. 2013 Jun;87(12):6851-65
pubmed: 23576505
Eur J Immunol. 2011 Aug;41(8):2248-59
pubmed: 21590767
J Virol. 2004 Mar;78(5):2255-64
pubmed: 14963122
J Immunol. 2009 Sep 15;183(6):3932-41
pubmed: 19692644
Nature. 2013 Oct 3;502(7469):100-4
pubmed: 24025770
PLoS One. 2011 Feb 03;6(2):e14646
pubmed: 21304910
Vaccine. 2015 May 5;33(19):2261-2266
pubmed: 25820063
Eur J Immunol. 2005 Apr;35(4):1113-23
pubmed: 15756645
PLoS Pathog. 2017 Aug 10;13(8):e1006507
pubmed: 28796839
Trends Immunol. 2012 Feb;33(2):84-90
pubmed: 22222196
Immunity. 2007 Aug;27(2):281-95
pubmed: 17723218
Eur J Immunol. 2013 May;43(5):1252-63
pubmed: 23404526
PLoS Pathog. 2016 Dec 15;12(12):e1006072
pubmed: 27977791
J Immunol. 2003 Feb 15;170(4):2022-9
pubmed: 12574372
J Immunol. 2013 Apr 1;190(7):3399-409
pubmed: 23460738
Nat Rev Immunol. 2016 Jun;16(6):367-77
pubmed: 27108521
J Immunol. 2019 Feb 1;202(3):943-955
pubmed: 30635396
Curr Top Microbiol Immunol. 2008;325:315-31
pubmed: 18637514
Sci Rep. 2016 Feb 15;6:21674
pubmed: 26876974
J Gen Virol. 2011 Sep;92(Pt 9):1994-2005
pubmed: 21632567
J Immunol. 2015 Nov 15;195(10):4792-801
pubmed: 26453748
Vaccine. 2012 Apr 26;30(20):3047-52
pubmed: 22414558
Blood. 2012 Feb 16;119(7):1702-12
pubmed: 22207739
Immunol Rev. 2018 May;283(1):161-175
pubmed: 29664565
J Exp Med. 1998 Sep 21;188(6):1047-54
pubmed: 9743523
Oncotarget. 2018 Jun 29;9(50):29392-29402
pubmed: 30034625
Front Immunol. 2018 Nov 20;9:2692
pubmed: 30515169
PLoS One. 2010 Mar 12;5(3):e9681
pubmed: 20300633
J Virol. 2016 Apr 14;90(9):4402-4411
pubmed: 26889035
J Immunol. 2013 Jun 1;190(11):5363-72
pubmed: 23636061
J Immunol. 2011 Apr 1;186(7):3874-81
pubmed: 21357256
J Immunother. 2012 Jun;35(5):390-9
pubmed: 22576344
J Immunol. 2013 Mar 15;190(6):2767-77
pubmed: 23390296
J Immunol. 2013 Apr 1;190(7):3410-6
pubmed: 23455500
Cancer Immunol Res. 2015 May;3(5):536-46
pubmed: 25633711
Front Immunol. 2018 May 07;9:991
pubmed: 29867968
Immunity. 2014 Dec 18;41(6):886-97
pubmed: 25526304
Eur J Immunol. 2007 Jun;37(6):1502-12
pubmed: 17492805
J Virol. 2006 Nov;80(21):10436-56
pubmed: 16928768
Eur J Immunol. 2015 Jan;45(1):113-8
pubmed: 25331015
Cell Rep. 2018 Apr 17;23(3):768-782
pubmed: 29669283
PLoS Pathog. 2017 Dec 27;13(12):e1006782
pubmed: 29281733
Sci Immunol. 2017 Jun 2;2(12):
pubmed: 28783656
Eur J Immunol. 2011 Sep;41(9):2612-8
pubmed: 21604258
Eur J Immunol. 2017 Aug;47(8):1354-1367
pubmed: 28612942
J Virol. 2009 Sep;83(17):8869-84
pubmed: 19535440
PLoS Pathog. 2011 Oct;7(10):e1002313
pubmed: 22046127
PLoS Pathog. 2014 Jul 03;10(7):e1004233
pubmed: 24992722
J Virol. 1988 Mar;62(3):987-97
pubmed: 2828694
Immunol Rev. 2018 May;283(1):99-112
pubmed: 29664577
Sci Immunol. 2017 Jan 6;2(7):
pubmed: 28783666
J Immunother Cancer. 2019 Jan 31;7(1):25
pubmed: 30704520
Elife. 2015 Aug 11;4:
pubmed: 26263500
Immunity. 2016 Dec 20;45(6):1270-1284
pubmed: 27939671
J Med Virol. 2013 Nov;85(11):1968-74
pubmed: 23852921
J Virol. 2002 Jan;76(1):151-64
pubmed: 11739681
J Immunol. 2015 Feb 15;194(4):1726-1736
pubmed: 25595792
Mucosal Immunol. 2017 Mar;10(2):545-554
pubmed: 27220815
Front Immunol. 2018 Aug 14;9:1861
pubmed: 30154789
Cell Rep. 2015 Nov 24;13(8):1578-88
pubmed: 26586434
Mol Ther. 2016 Aug;24(8):1444-55
pubmed: 27434584
Biochem Biophys Res Commun. 2013 Jul 26;437(2):287-91
pubmed: 23811402
J Immunol. 2010 Sep 15;185(6):3583-92
pubmed: 20713884
PLoS Pathog. 2018 Apr 13;14(4):e1006993
pubmed: 29652930
J Immunol. 2013 Apr 15;190(8):4162-74
pubmed: 23509359
J Exp Med. 1989 Apr 1;169(4):1199-212
pubmed: 2564415
PLoS Pathog. 2016 Sep 16;12(9):e1005895
pubmed: 27637068
J Gen Virol. 2016 Jan;97(1):185-195
pubmed: 26555192
Vaccine. 2018 Nov 12;36(46):7011-7016
pubmed: 30279090
J Immunol. 2005 Oct 1;175(7):4686-96
pubmed: 16177116
J Virol. 2011 Jan;85(1):390-6
pubmed: 20980516